100th Patient Successfully Treated Using CoreValve, S.A.'s ReValving™ Device To Non-Surgically Replace A Diseased Aortic Heart Valve

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve (www.corevalve.com) announced today that a total of 100 patients at nine worldwide investigative sites have now undergone percutaneous aortic valve replacement (PAVR) on a beating heart with the CoreValve Percutaneous ReValving™ System to treat either their aortic stenosis, aortic regurgitation, or failed-tissue-valve-prosthesis conditions.